A study in the management of phobic anxiety disorder using Hahnemanns method

A clinical verification on Hahnemanns method in management of Phobic Anxiety Disorder - A quasi experimental study - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/08/072740

Enrollment

Registered

2024-08-20

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F40- Phobic anxiety disorders

Interventions

Intervention1: Individualized homoeopathic medicine: Individualized homoeopathic medicine is given according to symptom similarity via orally in both acute and chronic conditions 1.In chronic cases th

Eligibility

Inclusion criteria

Inclusion criteria: participants satisfying case definition for Phobic anxiety disorder

Exclusion criteria

Exclusion criteria: 1.PAD with another psychiatric comorbidity 2.subjects who used psychotropic medicines in the past 2 weeks 3.subject who are pregnant or lactating 4.severe systemic illness using conventional medicine 5.substance-induced disorders 6.immunocompromised conditions like HIV, TB etc.

Design outcomes

Primary

Measure	Time frame
To decrease the intensity of symptoms in a patient arising due to phobias using individualized homoeopathic medicines. the change in intensity of symptoms is measured using American psychiatric association phobia scales, the decrease in total scores from baseline scores indicate good outcome.Timepoint: After medicinal prescription using American Psychiatric Association Phobia scale the changes will be assessed for every 1 month interval during monthly follow up for consecutive 6 months.	—

Measure

Time frame

To decrease the intensity of symptoms in a patient arising due to phobias using individualized homoeopathic medicines. the change in intensity of symptoms is measured using American psychiatric association phobia scales, the decrease in total scores from baseline scores indicate good outcome.Timepoint: After medicinal prescription using American Psychiatric Association Phobia scale the changes will be assessed for every 1 month interval during monthly follow up for consecutive 6 months.

—

Secondary

Measure	Time frame
The quality of life of people with phobic anxiety disorder is to be improved. The reduction in total scores of baseline to that of 6th month indicates good outcome of treatmentTimepoint: WHO quality of life questionnaire will be assessed during baseline & at 6th month of study after medicinal intervention & values are compared	—

Countries

India

Contacts

Public ContactDr Dhushara S

Government Homoeopathic Medical College

nbk251@gmail.com9400571035

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026